Since the different Abs have a similar “efficacy” in staining immune cells, but a distinct staining pattern for tumor cells with, e.g., a reduced capacity of tumor cell staining for SP142, the classification of a patient as PD-L1 positive or negative, and thus the eligibility for iCPI therapy highly relay on the performed staining. This evidence concerns the gene CD274 and neoplasm.